29 Gao J, Ward JF , Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 2017;23:551–5. 30 Zhao SG, Lehrer J, Chang SL, et al. The immune landscape of prostate cancer and nomination of PD- L2 as a potential therapeutic target. J Natl Cancer Inst 2019;111:301–10. 31 Redman JM, Steinberg SM, Gulley JL. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration- resistant prostate cancer. J Immunother Cancer 2018;6:91.